Clavis Pharma ASA : Clavis Pharma ASA : Invitation to presentation and webcast of Clavis Pharma's fourth quarter results 2012 Invitation to presentation and webcast of Clavis Pharma's fourth quarter results 2012 Oslo, Norway, 7 February 2013 Clavis Pharma ASA (OSE: CLAVIS) presents the company's fourth quarter 2012 results on Friday 15 February 2013 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway. The presentation will start at 08:30(CET). Following the presentation, there will be a Q&A session. Breakfast will be served from 08.00 (CET). The presentation will also be webcast live and can be accessed directly from WEBCAST or clavispharma.com. Questions can be submitted live during the presentation. The quarterly report and presentation will be available at clavispharma.com/investors. Clavis Pharma welcomes all interested parties. Contacts: Olav Hellebø Chief Executive Officer +47 24 11 09 50 email@example.com Gunnar Manum Chief Financial Officer +47 24 11 09 71 +47 95 17 91 90 (mob) firstname.lastname@example.org Mark Swallow / Nina Enegren / David Dible Citigate Dewe Rogerson +44 207 282 2948 email@example.com Peter Rahmer (US Investor enquiries) The Trout Group +1 646 378 2973 Direct / + 646 272 8526 Cell firstname.lastname@example.org About Clavis Pharma Clavis Pharma ASA is a clinical-stage pharmaceutical company developing novel anti-cancer drugs and companion diagnostics to identify patient populations that may benefit from treatment with these agents. Clavis' development pipeline includes novel patented versions of well-established and commercially successful drugs, made using the Company's proprietary Lipid Vector Technology (LVT), which may offer a better efficacy /safety profile compared to the parent compounds. The Company's lead product, Elacytarabine, is in a randomized, controlled Phase III study (the CLAVELA study) that recently completed recruitment in relapsed or refractory acute myeloid leukaemia. The Company is also investigating CP-4200, an azacitidine derivative, in preclinical studies for myelodysplastic syndrome, a disease that is often a precursor to leukaemia. Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities. Clavis Pharma is based in Oslo, Norway and listed on the Oslo Stock Exchange (ticker: CLAVIS). www.clavispharma.com Forward-looking statements This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Clavis Pharma ASA via Thomson Reuters ONE HUG#1676288
Clavis Pharma ASA : Clavis Pharma ASA : Invitation to presentation and webcast of Clavis Pharma's fourth quarter results 2012
Press spacebar to pause and continue. Press esc to stop.